Literature DB >> 21499819

Asymmetric dimethylarginine level in hyperglycemic gestation.

Ayse Cikim Sertkaya1, Ayse Kafkasli, Ilgin Turkcuoglu, Aysun Bay Karabulut.   

Abstract

We aimed to evaluate plasma asymmetric dimethylarginine (ADMA) concentrations and its relation with insulin sensitivity/resistance indices in pregnant women with different degrees of carbohydrate intolerance. This study included a two step approach; 50 g glucose challenge test (GCT) followed by 100 g oral glucose tolerance test (OGTT) was used for diagnosis of carbohydrate intolerance within 24-28th weeks of gestation. Pregnant women with positive GCT but negative OGTT (AGCT group, n=30) and gestational diabetics (GDM group, n=58) were compared to healthy pregnant controls (n=50). Plasma ADMA concentration and its relationship with glucose and insulin levels and insulin sensitivity/resistance indices (HOMA-IR, QUICKI, ISIOGTT) were evaluated. Both AGCT and GDM groups were found to have similarly higher plasma ADMA levels than control subjects (3.60±1.21; 4.00±1.70; 2.65±0.82 μmol/l, respectively, P=0.001). ADMA was significantly but slightly correlated with insulin sensitivity/resistance indices and moderately correlated with 2-h insulin level. The 2-h insulin value of the OGTT was the independent influencing constant for ADMA (R=0.57, P=0.0001). In conclusion, plasma asymmetric dimethylarginine level was higher in cases with abnormal glucose challenge test but normal OGTT as well as in gestational diabetics, compared to pregnant women with normal glucose tolerance. The elevated ADMA level in pregnant women with carbohydrate intolerance may possibly be due to elevated insulin level.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499819     DOI: 10.1007/s12020-011-9461-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  32 in total

1.  Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.

Authors:  Friedrich Schulze; Henrike Lenzen; Christoph Hanefeld; Asja Bartling; Karl J Osterziel; Lilia Goudeva; Caroline Schmidt-Lucke; Magda Kusus; Renke Maas; Edzard Schwedhelm; Dietrich Strödter; Bernd C Simon; Andreas Mügge; Werner G Daniel; Harald Tillmanns; Bernhard Maisch; Thomas Streichert; Rainer H Böger
Journal:  Am Heart J       Date:  2006-09       Impact factor: 4.749

Review 2.  Nitric oxide and atherosclerosis.

Authors:  C Napoli; L J Ignarro
Journal:  Nitric Oxide       Date:  2001-04       Impact factor: 4.427

3.  Is mild gestational hyperglycaemia associated with maternal and neonatal complications? The Diagest Study.

Authors:  A Vambergue; M C Nuttens; O Verier-Mine; C Dognin; J P Cappoen; P Fontaine
Journal:  Diabet Med       Date:  2000-03       Impact factor: 4.359

4.  Asymmetric dimethylarginine concentrations are elevated in women with gestational diabetes.

Authors:  Mujde Akturk; Alev Altinova; Ismail Mert; Aylin Dincel; Ayla Sargin; Umran Buyukkagnici; Metin Arslan; Nuri Danisman
Journal:  Endocrine       Date:  2010-07-11       Impact factor: 3.633

5.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  An abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normal.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Anthony J G Hanley; Bernard Zinman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-21       Impact factor: 3.478

7.  Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes.

Authors:  E Anastasiou; J P Lekakis; M Alevizaki; C M Papamichael; J Megas; A Souvatzoglou; S F Stamatelopoulos
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

8.  Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients.

Authors:  Dildar Konukoglu; Hafize Uzun; Sinem Firtina; Pinar Cigdem Arica; Ahmet Kocael; Mustafa Taskin
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

9.  Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis.

Authors:  Leanne Bellamy; Juan-Pablo Casas; Aroon D Hingorani; David Williams
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

10.  Isolated hyperglycemia at 1 hour on oral glucose tolerance test in pregnancy resembles gestational diabetes mellitus in predicting postpartum metabolic dysfunction.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Bernard Zinman; Anthony J G Hanley
Journal:  Diabetes Care       Date:  2008-03-20       Impact factor: 19.112

View more
  4 in total

1.  Asymmetric dimethylarginine is associated with high-sensitivity C-reactive protein and early carotid atherosclerosis in women with previous gestational diabetes mellitus.

Authors:  Wei Xia; Dajiang Li; Chunquan Zhang; Li Xu; Wenliang Xu; Yibing Shao
Journal:  Endocrine       Date:  2014-06-25       Impact factor: 3.633

2.  Increased asymmetric dimethylarginine levels in severe transient tachypnea of the newborn.

Authors:  D U Isik; A Y Bas; N Demirel; S Kavurt; O Aydemir; A V Kavurt; I Cetin
Journal:  J Perinatol       Date:  2016-02-11       Impact factor: 2.521

Review 3.  A systematic review of metabolite profiling in gestational diabetes mellitus.

Authors:  Jennifer Huynh; Grace Xiong; Rhonda Bentley-Lewis
Journal:  Diabetologia       Date:  2014-09-06       Impact factor: 10.122

4.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.